title: Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats.
abstract: Through the use of microanatomic techniques, we investigated the effects of treatment with some dihydropyridine-type calcium antagonists (CAs) (ie, lercanidipine, manidipine, and nicardipine) and with the nondihydropyridine-type vasodilator hydralazine on hypertension-dependent glomerular injury and on the morphology of afferent and efferent arterioles in spontaneously hypertensive rats (SHR). Fourteen-week-old male SHR and age-matched normotensive Wistar-Kyoto rats were left untreated (control groups). Four additional groups of 14-week-old SHR were treated for 12 weeks with daily oral doses of 2.5 mg/kg lercanidipine, 5 mg/kg manidipine, 3 mg/kg nicardipine, or 10 mg/kg hydralazine. These treatments decreased systolic blood pressure values to a similar extent in SHR. Signs of glomerular injury, as characterized by glomerulosclerosis, hypertrophy, and an increased number of mesangial cells, were observed in control SHR. The treatment with CAs improved glomerular morphology and decreased the number of mesangial cells. Lercanidipine and manidipine were more effective than nicardipine in countering glomerular injury. In the SHR, both afferent and efferent arterioles revealed luminal narrowing, accompanied by increased wall thickness in efferent arterioles. The dihydropyridine-type derivatives that were tested decreased the luminal narrowing of afferent arterioles. Lercanidipine and manidipine countered the luminal narrowing of efferent arterioles. Hydralazine had no effect on hypertension-dependent glomerular injury or vascular changes. The present data indicate that lercanidipine and manidipine vasodilate afferent and efferent arterioles in SHR. A vasodilatory activity on efferent arteriole, which is not induced by the majority of CAs, may represent an useful property in the treatment of hypertension complicated by renal disease.
authors.affiliation: Section of Human Anatomy, Departments of Pharmacological Sciences and Experimental Medicine and Comparative Morphology and Biochemical Sciences, University of Camerino, Camerino, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Sabbatini
authors.forename: A
authors.initials: A
authors.lastname: Leonardi
authors.forename: R
authors.initials: R
authors.lastname: Testa
authors.forename: L
authors.initials: L
authors.lastname: Vitaioli
authors.forename: F
authors.initials: F
authors.lastname: Amenta
mesh_terms: D000419:Albuminuria / Q000188:drug therapy; D000818:Animals; D001160:Arterioles / Q000187:drug effects / Q000473:pathology / Q000502:physiology; D002118:Calcium / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D004095:Dihydropyridines / Q000494:pharmacology*; D006830:Hydralazine / Q000494:pharmacology; D006977:Hypertension, Renal / Q000188:drug therapy; D007606:Juxtaglomerular Apparatus / Q000098:blood supply / Q000187:drug effects* / Q000473:pathology; D008297:Male; D009529:Nicardipine / Q000494:pharmacology; D009578:Nitrobenzenes; D010879:Piperazines; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D012079:Renal Circulation / Q000187:drug effects* / Q000502:physiology; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D009578:Nitrobenzenes; D010879:Piperazines; D014665:Vasodilator Agents; D006830:Hydralazine; C054218:manidipine; D009529:Nicardipine; D002118:Calcium; C060343:lercanidipine